<DOC>
	<DOCNO>NCT00531193</DOCNO>
	<brief_summary>To establish extent BIIB014 , follow 8 12 consecutive day dose select dose level , occupy brain 's A2A receptor . Receptor occupancy assess PET scan use radiolabelled tracer .</brief_summary>
	<brief_title>Using PET Scans Study Brain Receptor Occupancy BIIB014 Healthy Male Volunteers</brief_title>
	<detailed_description>Subjects enrol sequentially cohorts 2 4 subject . PET scan result determine actual number cohort enrol BIIB014 dose give subject . Since enrolled subject receive BIIB014 , study list 1-arm , Single Group study ( actual study design dose escalation ) . Participating subject require reside clinical unit 10 14 consecutive day . Participants receive 1 oral dose BIIB014 daily 8 12 consecutive day . During study , subject undergo 2 PET scan 1 MRI . Frequent blood sample pharmacokinetic assessment also perform .</detailed_description>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>3- ( 4-amino-3-methylbenzyl ) -7- ( 2-furyl ) -3H- ( 1,2,3 ) triazolo ( 4,5-d ) pyrimidine-5-amine</mesh_term>
	<criteria>BMI 18.0 29.0 kg/m2 Willing abstain caffeinecontaining product 1 week prior dose discharge unit . Willing able practice effective contraception 2 month follow last dose study drug . History severe allergic reaction clinically significant allergy . History malignancy , exclude adequately treat basal cell carcinoma . History clinically significant disease . History claustrophobia condition incompatible MRI/PET scanning . History exposure ionize radiation , exception dental xrays , within 12 month prior dose . Serious infection within 4 week prior dose . HbA1c &gt; 6 % , positive Hepatitis C Hepatitis B , presence HIV know exposure HIV , positive G6PD assay , clinically significant abnormal laboratory parameter Screening . Abnormal supine stand blood pressure orthostatic hypotension . Any prior treatment antipsychotic medication , dopamine antagonist , dopaminergic agonist . Treatment investigational drug within 3 month prior dose . Treatment prescription medication within 4 week prior dose . History drug alcohol abuse within 1 year prior dose . Current smoker tobacco use within 3 month prior dose . Heavy caffeine consumption within 4 week prior dose .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Healthy male volunteer</keyword>
</DOC>